






Novel method to analyse the Biomarker-strategy
design
Cornelia Ursula Kunza,b∗, Thomas Jakia, and Nigel Stallardc
Recent developments in genomics and proteomics enable the discovery of biomarkers that allow identification
of subgroups of patients responding well to a treatment. One currently used clinical trial design incorporating a
predictive biomarker is the so-called biomarker strategy design (or marker-based strategy design). Conventionally,
the results from this design are analysed by comparing the mean of the biomarker-led arm with the mean of the
randomised arm. Several problems regarding the analysis of the data obtained from this design have been identified
in the literature. In this paper, we show how these problems can be resolved if the sample sizes in the subgroups
fulfil the specified orthogonality condition. We also propose a novel analysis strategy that allows definition of
test statistics for the biomarker-by-treatment interaction effect as well as for the classical treatment effect and
the biomarker effect. We derive equations for the sample size calculation for the case of perfect and imperfect
biomarker assays. We also show that the often used 1:1 randomisation does not necessarily lead to the smallest
sample size. Application of the novel method is illustrated using a real data example.
Copyright c© 2010 John Wiley & Sons, Ltd.
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1. Introduction
The focus of modern medicine has shifted from broad spectrum treatments to targeted therapeutics leading to new
challenges for the design and analysis of clinical trials. Recent developments in genomics and proteomics enable the
discovery of biomarkers that allow identification of subgroups of patients responding well to a treatment. Often little is
known about this subset of patients until well into large-scale clinical trials [1].
The impact of genomic variability is often assessed in a biomarker-based design. The general question when using any
of these designs is whether different treatments should be recommended for different subgroups of patients. Establishing
clinical relevance of a biomarker test for guiding therapy decisions requires demonstrating that it can classify patients
into distinct subgroups with different recommended management [2]. Several clinical trial designs using a biomarker to
identify subgroups of patients likely to respond to a treatment have been proposed in the literature. The most commonly
used designs are the enrichment design and the biomarker stratified design [3, 4].
Another currently used design incorporating a predictive biomarker is the so-called biomarker strategy design (or
marker-based strategy design) [2, 5, 6]. Within this design patients are randomised to either have their treatment based
on the biomarker (i.e. biomarker positive patients receive a new treatment while biomarker negative patients receive the
standard treatment) or to be randomly assigned to treatment T or control group C (see Figure 1).
An alternative variant of the biomarker strategy design would not randomise patients in the randomised arm but treat
everyone in this arm with the control treatment (see, for example, [7, 2, 3]). Although this design is a special case of the
design described above (the probability to be randomised into the treatment arm is set to 0), this special case is more
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in Medicine C. U. Kunz
frequently used [8]. The main criticism here is that a huge proportion of the patients receive the same treatment (see, for
example, [9]). Furthermore, given that all patients in the randomised arm receive the control treatment, this variant of the
biomarker-strategy design cannot establish whether the new treatment would be beneficial for biomarker negative patients
as they all receive the control treatment (see, for example [3]).
Conventionally, the results of a biomarker-strategy design are analysed comparing the biomarker-led arm (arm B M)
to the randomised arm (arm R) (see Figure 1). The efficiency of this analysis has been investigated (see, for example,
[8, 10]). However, all criticism is focusing on special cases of the biomarker-stragety design: Firstly, they all assume that
randomisation to the biomarker-led and the randomised arm is equal. Secondly, Hoering et al. [8] and Young et al. [10] both
considered the special case of “no randomisation” in the randomised arm which means that all patients in that arm receive
the control treatment. Young et al. also consider the case of equal randomisation within the randomised arm. While equal
randomisation might be frequently used, it is not clear whether this minimises the sample size of the biomarker strategy
design. Furthermore, Young et al. investigate the efficiency of the design if there is either no treatment effect in the disease
negative patients or if the treatment effect in the disease negative patients is in the same direction as the treatment effect
for the positive patients (but only half as large). The main idea behind the biomarker strategy design is to test whether
there is a treatment-by-marker-interaction effect. This means that we assume effects for positive and negative patients to
be in opposite directions.

















pt + (1 −
p)(1 − s)
p(1 − t) + (1 − p)s
r2
1 − r2
Figure 1. Biomarker-strategy / Marker-based design
We hence extend the previous work in the following ways: (1) we investigate the efficiency of the design if the treatment
effect in the disease negative patients is in the opposite direction of the treatment effect for the biomarker positive patients,
(2) we investigate optimal randomisation rules for the design in order to minimise the sample size. Furthermore, we
propose a different way to analyse the data obtained from the biomarker strategy design. The “traditional” analysis does
not exploit all information that can be obtained from the data. Ru¨cker [11] proposed a two-stage randomised clinical
trial design which in principle corresponds to the biomarker strategy design with the only difference that patients in the
“non-randomised arm” (i.e. the biomarker-led arm) choose the treatment they prefer. However, she suggests an analysis
method that allows testing of the overall treatment effect, the self-selection effect and the preference effect. Walter et. al
[12] derive optimal randomisation rules for the above mentioned design by Ru¨cker. Their focus lies only on optimising
the first randomisation while they assume equal allocation to treatment and control in the randomised arm.
The aim of this paper is to adopt the analysis method proposed by Ru¨cker and extend it to the biomarker strategy design
by accounting for possible misclassifications using an imperfect assay.
2. Motivating example
Brusselle et. al [13] report the results from the AZISAST trial, a multicentre randomised double-blind placebo-controlled
trial. Patients with exacerbation-prone severe asthma received low-dose azithromycin or placebo as add-on treatment to a
combination therapy of inhaled corticosteroids and long-acting β2 agonists for 6 months. The primary outcome was the
rate of severe exacerbations and the lower respiratory tract infections (LRTI) requiring treatment with antibiotics during
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the 26-week treatment phase and one of the secondary endpoints was the forced expiratory volume in 1 s (F EV1). For the
primary endpoint as well as the above mentioned secondary endpoint, no effects were found for the overall population.
However, opposite effects were found for the primary endpoint for patients with either eosinophilic or non-eosinophilic
severe asthma. For the secondary outcome F EV1 they report a baseline value of 80.1 (standard deviation S D 21.9) for
the azithromycin group and a baseline value of 84.8 (20.7) for the placebo group. They also report a mean difference
(between baseline and 26 weeks) of -0.02 for the azithromycin group and a mean difference of -0.90 for the placebo
group. They do not report the values for the two subgroups (eosinophilic or non-eosinophilic severe asthma) so for our
illustrations, we therefore assume the following values: μT+ = 90, μT− = 70, μC+ = 75, and μC− = 95. Patients with
eosinophilic severe asthma are considered “positive”. Furthermore, we assume σT+ = σT− = σC+ = σC− = 20. For a
prevalence of p = 0.5, the effect in the treatment group is pμT+ + (1 − p)μT− = 80, for the control group the effect
is pμC+ + (1 − p)μC− = 85, and the overall treatment effect is pμT+ + (1 − p)μT− −
(
pμC+ + (1 − p)μC−
) = −5
which roughly reflects the effects observed in the AZISAST trial.
3. Notation
Let N denote the total sample size (assumed to be fixed), r1 denote the fraction of patients randomised to the biomarker-
led arm and let n B M = Nr1 denote the number of patients in the biomarker-led arm. Furthermore, let n R = N(1 − r1)
denote the number of patients in the randomised arm. Let r2 denote the fraction of patients within the randomised arm
that receive the experimental treatment and n T = N(1 − r1)r2 denote the sample size for this arm. Furthermore, let
nC = N(1 − r1)(1 − r2) denote the sample size for the control arm of the randomised arm. We assume that a block
randomisation is used so that the sample sizes n B M , nR , nT , and nC are fixed.
Within the biomarker-led arm patients have their biomarker assessed. Due to cost, ethical or administrative reasons
an imperfect assay is used to determine the true biomarker status. Let p denote the prevalence of the true biomarker
status and let t and s denote the sensitivity and specificity of the assay used. Without loss of generality, we assume that
patients with an observed positive biomarker status receive the experimental treatment while patients with an observed
negative biomarker status receive the control treatment. Let nT⊕ (nC ) denote the number of patients with an observed
positive (negative) biomarker status. The sample sizes follow binomial distributions with n T⊕ ∼ Binomial(Nr1, p⊕) and
nC ∼ Binomial(Nr1, p) with p⊕ = pt + (1 − p)(1 − s) and p = p(1 − t) + (1 − p)s = 1 − p⊕.
The primary endpoint of interest is denoted with Y and follows a normal distribution with mean μ T+ and variance σ 2T+
for truly biomarker positive patients receiving the experimental treatment, mean μT− and variance σ 2T− for truly biomarker
negative patients receiving the experimental treatment, mean μC+ and variance σ 2C+ for truly biomarker positive patients
receiving the control treatment, and mean μC− and variance σ 2C− for truly biomarker negative patients receiving the control
treatment. Table 1 gives an overview of some of the notation used.
Table 1. Notation
Biomarker (BM) led group Randomised group





t index T⊕ T
true mean ptμT+ + (1 − p)(1 − s)μT− – pμT+ + (1 − p)μT−













l index – C C
true mean – p(1 − t)μC+ + (1 − p)sμC− pμC+ + (1 − p)μC−











The traditional analysis of the biomarker-strategy design is to compare the mean of the biomarker-led arm μ B M with the
mean of the randomised arm μR (see, for example, [14]). The null hypotheses states that H T A0 : μB M = μR while the
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in Medicine C. U. Kunz
alternative hypothesis states that H T A1 : μB M = μR .










N (1−r1) . A test statistic for the hypothesis above is
then given by
Z B M − Z R√
V̂AR [Z B M − Z R]
. (1)
The expected value and variance of the test statistic as well as an estimator for the variance can be found in Appendix A.
4.1. Criticism
Although the biomarker strategy design is sometimes regarded as the gold standard, there is also a lot of criticism regarding
the trial design and the analysis of the data. The main problem with the traditional analysis is that it does not distinguish
between a situation where there is only an overall treatment effect (but no treatment-by-biomarker interaction effect), a
situation where there is only an interaction effect (but no treatment effect), and a situation where there is both a treatment
and an interaction effect. This “inability” leads to the following problems:
• Problem 1 “No interaction effect”: As mentioned above, the traditional analysis cannot distinguish between
the treatment and the interaction effect. If there is no interaction effect, we have μT+ − μC+ = μT− − μC− =
μT • − μC•. In this case, the expected value of the test statistic for the traditional analysis is E [μB M − μR] =
(t p + (1 − p)(1 − s) − r2) (μT • − μC•). So, as long as t p + (1 − p)(1 − s) − r2 = 0 and μT • − μC• = 0, we
observe a difference between the mean of the biomarker-led arm and the randomised arm even if there is no
treatment-by-biomarker interaction effect.
• Problem 2 “Biomarker useless”: As Freidlin, McShane, and Korn [2] noted before for a design with
r2 = 0, it is still possible to observe a difference between the means even if the biomarker is useless,






)+ (1 − p) (μT− − μC−)) which is the same as (0.5 − r2) times the “overall treatment effect”.
Hence, we would still observe a difference between the biomarker-led arm and the control arm (randomised arm)
as long as there is an “overall treatment effect” and 0.5 − r2 = 0. If the observed difference is positive, we would
recommend to use the biomarker to inform about the treatment a patients should receive although the biomarker is
not predictive.
• Problem 3 “Arbitrary randomisation”: The expected value of the test statistic for the traditional analysis depends
on the arbitrary randomisation ratio r2 since E [μB M − μR] = t p
(
μT+ − μC+






)+ (1 − p) (μT− − μC−)). It can be shown that if r2 = (pt (μT+ − μC+) + (1 − p)(1 −
s)(μT− − μC−))/(p(μT+ − μC+) + (1 − p)(μT− − μC−)) the differences between the two means is always zero
(E [μB M − μR] = 0) irrespective of the values of the other parameters.
4.2. Orthogonality condition
In the previous section, we have seen that the traditional analysis cannot distinguish between the treatment and
the interaction effect. Under Problem 1, we show that the expected value in case there is no interaction effect is
E [μB M − μR] = (t p + (1 − p)(1 − s) − r2) (μT • − μC•) = (p⊕ − r2) (μT • − μC•). One way of solving this problem
is to set r2 = p⊕ . This ensures that the traditional analysis is now a test for the interaction effect only and that if there is
no interaction effect the expected value of the test statistic is indeed 0. Hence, setting r2 = pT⊕ is a requirement in order
to be able to interpret the results of the traditional analysis.
We call this the “orthogonality condition” for the traditional analysis as it is similar to the “orthogonality condition”
in a two-way ANOVA, i.e. sample sizes in the different cells have to be proportional (in our case, n T⊕/nT = nC/nC )
in order to distinguish between the different effects [15]. This will also solve Problem 2 as setting r2 = p⊕ leads to
E [μB M − μR] = p(1 − p)(s + t − 1)
(




so that if t = s = 0.5, E [μB M − μR] = 0. Hence,
we do not observe a difference between the means of the biomarker-led armand the randomised arm if the biomarker is of
no use at all. We also solve Problem 3, as r2 is now fixed to p⊕ .
In general, the expected difference between the mean of the biomarker-led arm and the randomised arm can now only
be zero if (a) p = 0 or p = 1, (b) s + t = 1, or (c) μT+ − μC+ −
(
μT− − μC−
) = 0. Case (a) refers to a situation where
there are no subgroups to distinguish as every patients is either truly positive or truly negative, case (b) refers to a situation
where the biomarker is of no use to distinguish between truly positive and truly negative patients, and case (c) refers to a
situation where there is no treatment-by-biomarker interaction effect. While setting r2 to p⊕ fixes the problems regarding
the traditional analysis, in practice, the value of p⊕ is often unknown. Hence, a novel method that is robust to the choice
of r2 is preferable. Furthermore, there might be other reasons (ethical or financial) why a different value of r2 might be
chosen.
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5. Novel analysis method
In order to overcome the above mentioned disadvantage of the traditional analysis method, we propose a novel way to
analyse the data obtained from a biomarker-strategy design by defining three test statistics that clearly distinguish between
the treatment effect, the (so-called) biomarker effect, and the interaction effect.
5.1. Hypotheses
We define the following three effects: (1) the treatment effect, (2) the biomarker effect, and (3) the interaction effect with
corresponding null hypotheses
H T0 : μT − μC = pμT+ + (1 − p)μT− −
(
pμC+ + (1 − p)μC−










− μT− − μC−
2
= 0 (4)
5.2. Test statistics for the treatment, biomarker, and interaction effect
5.2.1. Test statistic for the treatment effect
The two means μT and μC can be estimated directly from the design by 1nT
∑nT
i=1 Yi,T = ZT R and 1nC
∑nC
i=1 Yi,C = ZC R ,
respectively. Hence, we can define a test statistic for the treatment effect as follows:
TT = ZT R − ZC R√
V̂AR [ZT R − ZC R]
(5)
The expected value and variance of the test statistic as well as an estimator for the variance is given in Appendix B.
5.2.2. Test statistics for the biomarker and the interaction effect
In the following, we derive test statistics for the biomarker and the interaction effect. Note that the null hypotheses for the
biomarker and the interaction effect depend on the means μT+ , μC+ , μT− , and μC− which cannot be estimated directly. Let
θT⊕ = t pμT+ + (1 − s)(1 − p)μT− and θC = (1 − t)pμC+ + s(1 − p)μC− . It can be shown that in the case that there




− μT− + μC−
2
= 0




− μT− − μC−
2
= 0
⇔H I0 : Nr1θT⊕ − Nr1μT (pt + (1 − p)(1 − s)) + (Nr1θC − Nr1μC(p(1 − t) + s(1 − p))) = 0 (7)



















It can be shown that the left-hand side of Equations (6) and (7) can be estimated by ZT − ZC and ZT + ZC , respectively.
Hence, a test statistic for the biomarker effect is given by:
TB = ZT − ZC√
V̂AR [ZT − ZC ]
(10)
and for the interaction effect by
TI = ZT + ZC√
V̂AR [ZT + ZC ]
. (11)
The expected values and variances as well as estimators for the variances can be found in Appendix C.
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5.3. Multiple testing
In cases where little is known about the new treatment under investigation and/or the biomarker used, it might be desirable
to test more than one hypotheses within the same trial. For example, we might be interested in simultaneously testing the
treatment and the interaction effect. Let COVT ,B , COVT ,I , and COVB,I denote the covariances between the test statistics
for the treatment and the biomarker effect (T,B), the treatment and the interaction effect (T,I), and the biomarker and the
interaction effect (B,I). The expected values of the covariances are given by:




σ 2T (1 − r2)(pt + (1 − p)(1 − s)) + σ 2Cr2(p(1 − t) + (1 − p)s)
)√




C + (1 − r2)σ 2T
) (12)




σ 2T (1 − r2)(pt + (1 − p)(1 − s)) − σ 2Cr2(p(1 − t) + (1 − p)s)
)√




C + (1 − r2)σ 2T
) (13)
COVB,I = VAR [ZT ] − VAR [ZC ]√VAR [ZT − ZC ]√VAR [ZT + ZC ] (14)




⎞⎠ approx.∼ N (μ, )
with
μ =
⎛⎝E [TT ]E [TB]
E [TI ]
⎞⎠ ,  =
⎛⎝ 1COVT ,B 1
COVT ,I COVB,I 1
⎞⎠
Functions like qmvnorm from the R-Package mvtnorm or the Mata function ghk() from Stata can be used in order
to find the adjusted critical values to control the overall type I error rate. However, in the following, we focus on testing
the interaction effect only, so no adjustment is made.
5.4. Sample size calculation
In the following, we give formulae to approximately calculate the sample sizes to test the different hypotheses given above.
To simplify the notation, let σT , σC , σT⊕ , σT , A, B, and C be defined as follows:
σ 2T =p
(
μ2T+ + σ 2T+
)
+ (1 − p)
(





μ2C+ + σ 2C+
)
+ (1 − p)
(





μ2T+ + σ 2T+
)
+ (1 − p)(1 − s)
(
μ2T− + σ 2T−
)
− θ2T⊕
σ 2C =p(1 − t)
(
μ2C+ + σ 2C+
)
+ (1 − p)s
(





T⊕ + σ 2C + p⊕ p
(
μ2T + μ2C
)− 2 (pμT θT⊕ + p⊕μCθC )
r1
+ (1 − r2)p
2⊕σ 2T + r2 p2σ 2C
(1 − r1)r2(1 − r2)
B =r1r2 p⊕ pσ
2
C + r1(1 − r2)p⊕ pσ 2T
(1 − r1)r2(1 − r2)
C = − θT⊕θC − p⊕ pμT μC + pμCθT⊕ + p⊕μT θC
The following equations give the sample sizes required to detect a certain effect for the traditional analysis (NT R), the
treatment effect (NT ), the biomarker effect (NB ), and the interaction effect (NI ) based on a two two-sided test with type I
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θT⊕ + θC − (r2μT + (1 − r2)μC)












)2 (1 − r2)σ 2T + r2σ 2C




θT⊕ − θC − p⊕μT + pμC
)2 (




√√√√( z1−α/2 + z1−β
θT⊕ − θC − p⊕μT + pμC
)4 (













θT⊕ + θC − p⊕μT − pμC
)2 (




√√√√( z1−α/2 + z1−β
θT⊕ + θC − p⊕μT − pμC
)4 (










It can be seen that all sample sizes depend on the randomisation ratios r1 and r2. Optimal solutions can be found using
a grid search.
6. Results
Based on the results for the AZISAST trial (see Section2), we calculated the sample sizes for the traditional analysis
and the interaction effect for different values of the prevalence p (from 0 to 1 in steps of 0.01), and the sensitivity t and
specificity s (from 0.5 to 1 in steps of 0.1) for a two-sided type I error of α = 0.05 and a power of 80%. For the traditional
analysis, r2 is set to p⊕ (as explained in Section 4.2). In order to find the optimal value for r1, we calculated the sample
sizes for values of r1 from 0 to 1 in steps of 0.01. The randomisation ratio r1 is then chosen so that the resulting sample
size is minimised. Obviously, choosing smaller increments will yield a more accurate value for r1. For the interaction
effect, we used a grid search over r1 and r2 (from 0 to 1 in steps of 0.01). For each combination of r1 and r2 we calculated
the resulting sample sizes and chose the combination that minimises the sample size for given values of p, t , and s. In
order to verify the obtained sample sizes, we simulated 10,000 data sets and estimated the resulting type I error and power
for different scenarios (see Appendix D).
6.1. Results for the traditional analysis
The left-hand side of Figure 2 shows the minimal sample sizes needed for the traditional analysis depending on the
prevalence p, the sensitivity t , the specificity s for the AZISAST trial. The black solid line shows the sample sizes for a
perfect biomarker, the grey solid line for a biomarker with t = s = 0.9, and the black dashed line for a biomarker with
t = s = 0.8. The labels show the optimal value for the randomisation ratio r1 (when r2 is set to p⊕).
As expected, we see that the sample size for the perfect biomarker is smaller than the sample sizes for an imperfect
biomarker with the sample size getting larger the smaller the values for t and s. We also see that the sample size increases
with smaller and larger values for the prevalence p. The sample size for the traditional analysis is smallest for a perfect
biomarker, a prevalence of p = 0.5, and randomisation ratios of r1 = 0.47. In this case, only 142 patients would be needed.
If the prevalence is 0.15, the sample size increases to 516 for the perfect biomarker.
For an imperfect biomarker with t = s = 0.9, the sample size is 231 for a prevalence of 0.5 and hence, in comparison
to a perfect biomarker, we already need nearly 90 patients more. For a prevalence of 0.15, the sample size increases to
853 and therefore, nearly 340 more patients are needed in comparison to the perfect biomarker. The sample sizes are even
larger when the sensitivity and specificity are 0.8. In this case, 423 patients are needed if p = 0.5 and 1580 if p = 0.15.
Compared to the case of a perfect biomarker, the sample sizes approximately triple.
In general, it should be noted that the optimal value for r1 is not necessarily 0.5 but varies between 0.47 and 0.51.
However, for a prevalence between 0.05 and 0.95, the difference in sample sizes for the optimal value of r1 and r1 = 0.5
is less than one patient. Therefore, in most cases r1 can be set to 0.5 without a noticeable change in the sample size.
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Figure 2. Minimal sample sizes for the traditional analysis and the interaction effect depending on the prevalence p, the sensitivity t , the specificity s, and the randomisation ratios
r1 and r2.
6.2. Results for the interaction effect
In the following we show the results for the sample sizes for testing the interaction effect based on our proposed analysis
method. The right-hand side of Figure 2 shows the resulting sample sizes for the interaction effect. As before, the black
solid line shows the sample sizes for the perfect biomarker, the grey solid line for a biomaker with t = s = 0.9, and the
black dashed line for a biomarker with t = s = 0.8. Labels show the optimal values for r1 and r2 so that the sample size































































































relative differences in sample sizes
Figure 3. Sample sizes for the traditional analysis and the interaction effect depending on the prevalence p, the sensitivity t , the specificity s, and the randomisation ratios r1 and
r2.
Again, we see that the sample sizes are smaller for prevalences around 0.5 and increase towards smaller and larger
values. For example, for a perfect biomarker and a prevalence of 0.5, the minimal sample size for the interaction effect is
142. It increases to 250 if the prevalence is 0.25 and to 530 if the prevalence is only 0.15. We also see that (as expected)
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larger sample sizes are needed if the biomarker is not perfect. For example, for an imperfect biomarker with t = s = 0.9,
the minimal sample size is 231 (for p = 0.5), 400 (for p = 0.25), and 836 (for p = 0.15). For an imperfect biomarker
with t = s = 0.8, the following sample sizes result: 422 (for p = 0.5), 722 (for p = 0.25), and 1498 (for p = 0.15).
As for the traditional analysis, we note that the optimal value for the randomisation ratio r 2 is r2 = p⊕ . However,
while this is a requirement for the traditional analysis in order for the results to be interpretable (see Section 4.2), for the
interaction effect setting r2 to p⊕ minimises the sample size but is not necessary in order to interpret the results of the test
statistic.
We also see that the optimal value for r1 is not necessarily 0.5 but ranges between 0.47 and 0.5. Again, the differences
between the minimal sample size and the one obtained for r1 = 0.5 is less than one patient as long as the second
randomisation ratio r2 is chosen so that the sample size is minimised given r1. The situation changes noticeably if both
randomisation rules are set to 0.5 which is frequently done. Let N0.5,0.5 denote the sample size for the interaction effect
for r1 = r2 = 0.5 and let Nmin denote the minimal sample size. Figure 3 shows the absolute difference in the sample sizes
(N0.5,0.5 − Nmin , left-hand side) and the relative differences (N0.5,0.5/Nmin , right-hand side). As we can see, the absolute
differences vary between 0 and approximately 130 (for a prevalence between 0.15 and 0.85). The absolute difference is
even larger for smaller (and higher) values of the prevalence. While we see that the absolute difference of the sample sizes
does not depend on the sensitivity and specificity of the biomarker, we see that the relative difference does (see right-hand



































































































relative differences in sample size in %
Figure 4. Differences in sample sizes for the traditional analysis and the interaction effect depending on the prevalence p, the sensitivity t , and the specificity s.
Figure 4 shows the absolute differences in sample size for the traditional analysis and the novel analysis for the
interaction effect (left-hand side) as well as the relative differences in sample size in percent (right-hand side) . As we can
see, the sample size for the traditional analysis is often higher than the sample size for the interaction effect (except for a
perfect biomarker where the sample size for the traditional design is always lower than the sample size for the interaction
effect). The absolute difference in the sample size might be substantial: for example, for t = s = 0.7 and p = 0.15 the
absolute difference in sample size is 268. The relative increase in the sample size is about 8% (from NI = 3388 to
NT R = 3656). We can also see that in cases where the sample size for the traditional analysis is smaller than the sample
size for the interaction effect, the increase in sample size is less than 3%. For example, for t = s = 1 and p = 0.15 the
sample size increases from NT R = 516 to NI = 530.
7. Conclusion
This paper investigates the performance of the traditional analysis of the biomarker-strategy design. We derive optimal
randomisation rules in order to minimise the sample size for the traditional analysis. We also propose a novel analysis
method for the data obtained from such a design and explore the properties of this method.
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The traditional analysis has been criticised many times (see, for example, [9, 2, 16, 17]). The main problems are that the
traditional analysis does not distinguish between the treatment and the interaction effect. Hence, it is possible to observe
no difference between the mean of the biomarker-led arm and the randomised arm even if there is an interaction effect or
to observe a difference between the means even if there is no interaction effect. We show that if the sample sizes in the
four subgroups of the biomarker-strategy design fulfil the “orthogonality condition” (i.e. are proportional to each other),
the above mentioned problems can be solved. However, while the “orthogonality condition” ensures that the traditional
analysis provides a test statistic for the interaction effect only, the value of p⊕ is often not known as it depends on the true
values for the sensitivity, the specificity, and the prevalence. These values are often unknown at the planning stage of a
trial.
To overcome the disadvantages of the traditional analysis, we propose a novel analysis method based on the work of
Ru¨cker [11]. We define three different effects than can be measured within the biomarker-strategy design: the treatment
effect, the biomarker effect, and the interaction effect. This ensures that our analysis can clearly distinguish between the
treatment effect and the interaction effect, regardless of the randomisation rules used. We derive test statistics and show
how the sample sizes for the three effects can be calculated. Optimal randomisation rules are derived in order to minimise
the sample sizes.
Furthermore, we show that if the “orthogonality condition” is fulfilled, the sample size for the interaction effect (based
on the novel analysis method) is often smaller than the sample size for the traditional analysis. In cases where the sample
size for the novel analysing method is larger than the sample size for the traditional analysis, the difference is less than 3%
of the sample size and therefore often negligible. In general, we therefore recommend to use the novel analysis method
instead of the traditional analysis method.
Appendix A. Traditional analysis
The expected value and variance of the test statistic for the traditional analysis are given by:
E [Z B M − Z R] =(t − r2)p
(
μT+ − μC+
)+ (1 − s − r2)(1 − p) (μT− − μC−)
=t p (μT+ − μC+)+ (1 − s)(1 − p) (μT− − μC−)− r2 (p (μT+ − μC+)+ (1 − p) (μT− − μC−))
(19)
VAR [Z B M − Z R] =
pt
(
μ2T+ + σ 2T+
)
+ (1 − p)(1 − s)
(
μ2T− + σ 2T−
)





μ2C+ + σ 2C+
)
+ (1 − p)s
(
μ2C− + σ 2C−
)




t pμT+ + (1 − p)(1 − s)μT−
) (







μ2T+ + σ 2T+ −
(
μ2C+ + σ 2C+
))
+ (1 − p)
(
μ2T− + σ 2T− −
(













μ2C+ + σ 2C+
)
+ (1 − p)
(
μ2C− + σ 2C−
)
− (pμC+ + (1 − p)μC−)2
N(1 − r1) . (20)
The variance can be estimated by



























(N(1 − r1))2 +
N(1 − r1)(1 − r2)∑C y2 − (∑C y)2
(N(1 − r1))2 (21)
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Appendix B. Treatment effect
The expected value and variance of the test statistic for the treatment effect are given by:
E [ZT R − ZC R] = p
(
μT+ − μC+
)+ (1 − p) (μT− − μC−) (22)
VAR [ZT R − ZC R] =




C+ + σ 2C+) + (1 − p)(μ2C− + σ 2C−) − (pμC+ + (1 − p)μC−)2
N(1 − r1)(1 − r2) . (23)
The variance can be estimated by
V̂AR [ZT R − ZC R] = =
∑
T y




(N(1 − r1)r2)(N(1 − r1)r2 − 1) +
∑
C y




(N(1 − r1)(1 − r2))(N(1 − r1)(1 − r2) − 1) (24)
Appendix C. Biomarker and interaction effect
The expected values are given by:
E [ZT ] =Nr1θT⊕ − Nr1μT (pt + (1 − p)(1 − s)) (25)
E [ZC ] =Nr1θC − Nr1μC (p(1 − t) + s(1 − p)) (26)
The variances are given by:
VAR [ZT ] =Nr1
(
pt (μ2T+ + σ 2T+) + (1 − p)(1 − s)(μ2T− + σ 2T−) − (ptμT+ + (1 − p)(1 − s)μT−)2
)
+ Nr1 p+(1 − p+)μ2T + ((Nr1 p+)2 + Nr1 p+(1 − p+))
σ 2T
N(1 − r1)r2
− 2 (Nr1μT (t pμT+ + (1 − p)(1 − s)μT−)(1 − p+)) (27)
VAR [ZC ] =Nr1
(
p(1 − t)(μ2C+ + σ 2C+) + (1 − p)s(μ2C− + σ 2C−) − (p(1 − t)μC+ + (1 − p)sμC−)2
)
+ Nr1 p−(1 − p−)μ2C + ((Nr1 p−)2 + Nr1 p−(1 − p−))
σ 2C
N(1 − r1)(1 − r2)
− 2 (Nr1μC((1 − t)pμC+ + (1 − p)sμC−)(1 − p−)) (28)
(29)
and the covariance by:
COV [ZT , ZC ] =Nr1
(− (t pμT+ + (1 − p)(1 − s)μT−) ((1 − t)pμC+ + s(1 − p)μC−)− p⊕ pμT μC
+ pμC
(
t pμT+ + (1 − p)(1 − s)μT−
)+ p⊕μT ((1 − t)pμC+ + s(1 − p)μC−)) . (30)
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The variances and covariances of ZT and ZC can be estimated by follows:






)2 −∑nT⊕i=1 Y 2i












































)2 −∑nCi=1 Y 2i





































































































The derivations can be found in the Supplemental Material. We anticipate the test statistics to approximately follow a
normal distribution.
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Appendix D. Simulation results for the type I error and power
In order to verify the sample sizes obtained in Section 6, we simulated 10,000 data sets and estimated the resulting type I
error and power. The power was estimated using the same values as described in Sections 2 and 6. For the type I error, the
means were set to μT+ = 90, μT− = 70, μC− = 75, and μC− = 55 (i.e. assuming that there is no interaction effect).
Table 2. Results for the power based on 10,000 simulations for different values of p, t , s, r1, and r2
interaction effect traditional analysis
p t s r1 r2 NI α 1 − β r1 r2 NT rad α 1 − β
0.15 0.8 0.8 0.50 0.29 1498 0.0499 0.7927 0.51 0.29 1580 0.0520 0.8211
0.15 0.9 0.9 0.50 0.22 836 0.0510 0.7938 0.50 0.22 853 0.0466 0.8083
0.15 1.0 1.0 0.49 0.15 530 0.0475 0.7877 0.49 0.15 516 0.0482 0.7884
0.20 0.8 0.8 0.50 0.32 974 0.0518 0.7995 0.51 0.32 1015 0.0473 0.8147
0.20 0.9 0.9 0.49 0.26 541 0.0467 0.7939 0.50 0.26 549 0.0461 0.7985
0.20 1.0 1.0 0.49 0.20 341 0.0486 0.7964 0.48 0.20 333 0.0462 0.7795
0.25 0.8 0.8 0.49 0.35 722 0.0500 0.7892 0.50 0.35 745 0.0489 0.8065
0.25 0.9 0.9 0.49 0.30 400 0.0489 0.7967 0.49 0.30 404 0.0473 0.7963
0.25 1.0 1.0 0.48 0.25 251 0.0498 0.7943 0.48 0.25 246 0.0490 0.7876
0.30 0.8 0.8 0.49 0.38 584 0.0478 0.7987 0.50 0.38 598 0.0470 0.8086
0.30 0.9 0.9 0.49 0.34 322 0.0451 0.7900 0.49 0.34 325 0.0533 0.7986
0.30 1.0 1.0 0.48 0.30 201 0.0490 0.7925 0.48 0.30 198 0.0500 0.7830
0.35 0.8 0.8 0.49 0.41 503 0.0462 0.7912 0.50 0.41 512 0.0503 0.8029
0.35 0.9 0.9 0.49 0.38 277 0.0480 0.7870 0.49 0.38 278 0.0473 0.7982
0.35 1.0 1.0 0.48 0.35 172 0.0468 0.7757 0.48 0.35 170 0.0473 0.7697
0.40 0.8 0.8 0.49 0.44 455 0.0478 0.7904 0.50 0.44 461 0.0506 0.7994
0.40 0.9 0.9 0.48 0.42 250 0.0497 0.7829 0.49 0.42 251 0.0496 0.7891
0.40 1.0 1.0 0.47 0.40 154 0.0477 0.7882 0.47 0.40 154 0.0500 0.7787
0.45 0.8 0.8 0.49 0.47 430 0.0476 0.7856 0.49 0.47 433 0.0471 0.8060
0.45 0.9 0.9 0.48 0.46 235 0.0479 0.7817 0.49 0.46 236 0.0488 0.7902
0.45 1.0 1.0 0.47 0.45 145 0.0460 0.7799 0.47 0.45 145 0.0445 0.7885
0.50 0.8 0.8 0.49 0.50 422 0.0493 0.7967 0.49 0.50 423 0.0489 0.7974
0.50 0.9 0.9 0.48 0.50 231 0.0485 0.7865 0.48 0.50 231 0.0455 0.7795
0.50 1.0 1.0 0.47 0.50 142 0.0396 0.7636 0.47 0.50 142 0.0436 0.7613
0.55 0.8 0.8 0.49 0.53 430 0.0463 0.7922 0.49 0.53 430 0.0494 0.7858
0.55 0.9 0.9 0.48 0.54 235 0.0449 0.7841 0.48 0.54 235 0.0460 0.7834
0.55 1.0 1.0 0.47 0.55 145 0.0460 0.7809 0.47 0.55 145 0.0447 0.7870
0.60 0.8 0.8 0.49 0.56 455 0.0482 0.7939 0.49 0.56 454 0.0511 0.7959
0.60 0.9 0.9 0.48 0.58 250 0.0484 0.7847 0.48 0.58 249 0.0467 0.7791
0.60 1.0 1.0 0.47 0.60 154 0.0492 0.7966 0.47 0.60 154 0.0471 0.7973
0.65 0.8 0.8 0.49 0.59 503 0.0498 0.7998 0.49 0.59 501 0.0521 0.8003
0.65 0.9 0.9 0.49 0.62 277 0.0459 0.7881 0.49 0.62 275 0.0430 0.7891
0.65 1.0 1.0 0.48 0.65 172 0.0412 0.7645 0.48 0.65 170 0.0390 0.7657
0.70 0.8 0.8 0.49 0.62 584 0.0510 0.7985 0.49 0.62 582 0.0488 0.7921
0.70 0.9 0.9 0.49 0.66 322 0.0465 0.7908 0.49 0.66 320 0.0492 0.7888
0.70 1.0 1.0 0.48 0.70 201 0.0528 0.7974 0.48 0.70 198 0.0452 0.7855
0.75 0.8 0.8 0.49 0.65 722 0.0481 0.7958 0.49 0.65 720 0.0496 0.7915
0.75 0.9 0.9 0.49 0.70 400 0.0496 0.7942 0.49 0.70 396 0.0466 0.7875
0.75 1.0 1.0 0.48 0.75 251 0.0567 0.8028 0.48 0.75 246 0.0524 0.7891
0.80 0.8 0.8 0.50 0.68 974 0.0476 0.8042 0.50 0.68 974 0.0501 0.8010
0.80 0.9 0.9 0.49 0.74 541 0.0453 0.7931 0.49 0.74 536 0.0496 0.7895
0.80 1.0 1.0 0.49 0.80 341 0.0524 0.7901 0.48 0.80 333 0.0475 0.7860
0.85 0.8 0.8 0.50 0.71 1498 0.0517 0.7920 0.50 0.71 1506 0.0509 0.8039
0.85 0.9 0.9 0.50 0.78 836 0.0505 0.7955 0.49 0.78 829 0.0558 0.7971
0.85 1.0 1.0 0.49 0.85 530 0.0481 0.7887 0.49 0.85 516 0.0475 0.7904
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